Skip to main content
. Author manuscript; available in PMC: 2008 May 2.
Published in final edited form as: Arch Dermatol. 2007 Jan;143(1):21–28. doi: 10.1001/archderm.143.1.21

Figure 3.

Figure 3

Cost-effectiveness acceptability curve for screening every 2 years compared with 1-time screening in 3 populations. CE indicates cost-effectiveness; QALY, quality-adjusted life year.